2-Methylthioadenosine diphosphate trisodium (Synonyms: 2-MeSADP, 2-Methylthio-ADP)

2-Methylthioadenosine diphosphate trisodium is a potent purinergic P2Y receptors agonist, with EC50s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-Methylthioadenosine diphosphate trisodium has pEC50s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-Methylthioadenosine diphosphate trisodium induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1[1][2][3].

2-Methylthioadenosine diphosphate trisodium (2-Methylthio-ADP trisodium) is a powerful aggregating agent for human platelets. 2-Methylthioadenosine diphosphate trisodium is also a powerful inhibitor of the accumulation of cyclic AMP in intact platelets exposed to PGE1 and a phosphodiesterase inhibitor[1].

[1]. Zhang FL, et al. P2Y(13): identification and characterization of a novel Galphai-coupled ADP receptor from human and mouse. J Pharmacol Exp Ther. 2002;301(2):705-713. [2]. Sak K, et al. A retrospective of recombinant P2Y receptor subtypes and their pharmacology. Arch Biochem Biophys. 2002;397(1):131-136. [3]. Macfarlane DE, et al. 2-Methylthioadenosine[beta-32P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets. J Clin Invest. 1983;71(3):420-428.